Tivdak

tisotumab vedotin · Genmab A/S
AUTHORISED IN THE EU

What Tivdak is used for

Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy (see section 5.1).

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Tivdak
Active substance
tisotumab vedotin
Disease area
Uterine Cervical Neoplasms
Medicine group
Antineoplastic agents
ATC code
L01FX23
Marketing authorisation holder
Genmab A/S
Authorised in the EU since
2025

Official information

In the USA

Same active substance: Tivdak

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Tivdak used for?

Tivdak as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy (see section 5.1).

What is the active substance in Tivdak?

Tivdak contains tisotumab vedotin.

Who makes Tivdak?

The EU marketing authorisation holder is Genmab A/S.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.